Verition Fund Management
VRDN icon

Verition Fund Management’s Viridian Therapeutics VRDN Stock Holding History

Verition Fund Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,072
Closed -$1.4M – 3635
2025
Q4 		$1.4M Buy
45,072
+34,752
+337% +$953K 0.01% 1894
2025
Q3 		$223K Sell
10,320
-43,605
-81% -$786K ﹤0.01% 3436
2025
Q2 		$754K Buy
53,925
+36,288
+206% +$492K ﹤0.01% 2672
2025
Q1 		$238K Buy
+17,637
New +$300K ﹤0.01% 2976
2023
Q3 		– Sell
-13,300
Closed -$316K – 2732
2023
Q2 		$316K Buy
13,300
+300
+2% +$7.7K ﹤0.01% 1524
2023
Q1 		$331K Buy
+13,000
New +$417K 0.01% 1459

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return